| USV has evolved from
a reliable producer of Dosage Forms and APIs to a process-driven
and research-focused company with an emerging global base.
The focus on research in protein and peptide production by recombinant
and chemical synthesis has yielded excellent results, with most
of the molecules being ready for pilot level scale-up.
USV has also entered into a license agreement with Biotech Consortium India Ltd. (BCIL) to scale-up, manufacture and market a novel conjugate typhoid vaccine developed by a team of scientists at the All India Institute of Medical Sciences (AIIMS), New Delhi. The project is supported by the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India. This project would give USV a foray into the new niche area of vaccines.
| Achievements |
- Robust and scalable processes for production of Bio-similar recombinant proteins and peptides
- Successful development of ART media
- Synthesis of eptifibatide which has been made available
in the Indian market.
|
| Capabilities |
| The P2 BRL includes
|
- Molecular Biology (genetic engineering)
- Tissue Culture
- Microbiology
- Fermentation
- Peptide & Nucleotide
- Protein Purification, and
- Analytical facilities to support the above
|
| 
